• ISRIB (trans-isomer): From ISR Modulation to Memory Preserva

  2026-07-08

  Discover how ISRIB (trans-isomer), a leading PERK inhibitor, uniquely enables researchers to dissect the integrated stress response’s role in memory and disease. This article explores recent breakthroughs in cognitive memory enhancement and experimental design.

• Refining In Vitro Drug Response Metrics in Cancer Evaluation

  2026-07-08

  Schwartz's dissertation advances the evaluation of anti-cancer agents by dissecting the relationship between growth inhibition and cell death in vitro. The work proposes refined measurement strategies, improving mechanistic insight and translational relevance for drug screening.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Research

  2026-07-07

  AZD0156 sets a new benchmark for selective ATM kinase inhibition, transforming how researchers dissect DNA damage response and checkpoint control in cancer models. Discover advanced protocols, troubleshooting insights, and translational strategies to unlock the full potential of this potent DNA damage response inhibitor.

• Targeting p16: Antibody Fragment-Drug Conjugates in Cancer T

  2026-07-07

  This study introduces a novel antibody fragment-drug conjugate (AFDC) that targets p16, a cell cycle regulator overexpressed in several aggressive cancers. The innovation lies in using a humanized single-chain antibody fragment fused with a cell-penetrating peptide to selectively deliver cytotoxic drugs to p16-high cancer cells, demonstrating strong in vitro antitumor activity and highlighting a new direction for targeted therapy.

• Streptozotocin for Experimental Diabetes: Protocols & Insigh

  2026-07-06

  Streptozotocin (STZ) is the gold standard for reproducible β-cell apoptosis induction and experimental diabetes mellitus modeling. This guide translates the latest research and troubleshooting strategies into actionable workflows, empowering diabetes researchers to optimize outcomes and explore neuroimmune complications with precision.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Therapy R

  2026-07-06

  AZD0156 empowers researchers to precisely modulate DNA damage response and checkpoint control in cancer models, with proven synergy in HR-proficient ovarian cancer. This article delivers hands-on workflow guidance, troubleshooting insights, and data-driven protocol optimization for selective ATM kinase inhibitor studies.

• Mechanism-Based Discovery of TB DHFR Inhibitors via HTS Inte

  2026-07-05

  Santa Maria et al. present an innovative framework that integrates high-throughput biophysical profiling with machine learning to elucidate mechanisms of action and identify new inhibitors of Mycobacterium tuberculosis dihydrofolate reductase (Mtb DHFR). This approach bridges phenotypic and target-based screening, accelerating the identification of antibacterial agents with defined molecular targets.

• Isoprinosine: Protocols and Innovations for Immunomodulatory

  2026-07-04

  Harness Isoprinosine's dual antiviral and immunomodulatory actions to refine workflows targeting herpesvirus and acute respiratory infections. This guide distills protocol enhancements, integration with host-factor discoveries, and troubleshooting insights for bench scientists seeking translational impact.

• Itraconazole: Advanced Workflows for Antifungal Research Suc

  2026-07-03

  Itraconazole stands out as a triazole antifungal agent, delivering robust antifungal activity and versatile modulation of CYP3A4 for advanced research modeling. This article translates the latest bench findings into actionable workflows and troubleshooting strategies, empowering researchers tackling Candida biofilm resistance and antifungal drug interaction studies.

• IGF2BP1-m6A-TUBB4B Axis Drives Hepatic Stellate Cell Activat

  2026-07-03

  This study reveals that the m6A reader IGF2BP1 is a crucial regulator of hepatic stellate cell (HSC) activation by stabilizing TUBB4B mRNA in an m6A-dependent manner. These findings illuminate a mechanistic link between RNA modifications and liver fibrosis, presenting new molecular targets for antifibrotic strategies.

• Azithromycin in Bacterial Infection Research: Protocols & Pi

  2026-07-02

  Azithromycin stands out as a macrolide antibiotic for advanced bacterial infection and resistance studies, offering robust experimental flexibility. This guide delivers actionable protocols, troubleshooting insights, and a nuanced perspective on resistance trends, with workflows backed by recent peer-reviewed research.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-07-02

  The referenced study elucidates how MLKL polymerization triggers lysosomal membrane permeabilization (LMP), leading to the release of cathepsin B and promoting necroptosis. These findings clarify the mechanistic link between lysosomal enzyme release and regulated cell death, opening new avenues for targeted cell death modulation in disease models.

• Sulfo-NHS-SS-Biotin: Precision Protein Labeling for Affinity

  2026-07-01

  Sulfo-NHS-SS-Biotin stands out as a cleavable biotin disulfide N-hydroxysulfosuccinimide ester, enabling highly specific, reversible cell surface protein labeling—ideal for affinity purification and advanced proteomics. Its unique water solubility and disulfide-cleavable spacer arm facilitate streamlined, contamination-minimizing workflows that outpace conventional biotinylation reagents.

• Pregnenolone Carbonitrile: Precision Control of Hepatic and

  2026-07-01

  Explore how Pregnenolone Carbonitrile enables precise, differential regulation of cytochrome P450 enzymes in the liver and brain. Uncover unique mechanisms—beyond classical PXR activation—that inform advanced hepatic detoxification studies and neuroprotection research.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-06-30

  This EDTA-free Protease Inhibitor Cocktail prevents artifactual protein degradation during extraction and analysis, supporting workflows that require divalent cation compatibility such as phosphorylation studies and kinase assays. It should not be used in protocols requiring EDTA-mediated chelation or those incompatible with DMSO-based solutions.

15377 records 2/1026 page Previous Next 12345 下5页 Last page